Health care is a recession-proof sector, since folks will continue to take their medications no matter how bad the market gets. However, it��s important to understand that some of the biggest names in Big Pharma continue to struggle under the weight of looming patent expirations — companies like Pfizer (NYSE:PFE), Merck (NYSE:MRK) and others. That��s why health care investors should consider up-and-coming biotech stocks as part of their portfolio. These biotechnology companies could be working on tomorrow��s blockbuster drug, not profiting from an old idea that will soon be out of their patent protection.
I watch more than 5,000 publicly traded companies with my Portfolio Grader tool, ranking companies by a number of fundamental and quantitative measures. This week I’ve got 9 booming biotech stocks to buy.
Here they are, in alphabetical order. Each one of these stocks gets an ��A�� or ��B�� according to my research, meaning it is a ��strong buy�� or ��buy.��
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) develops and commercializes products for hematology, neurology, ophthalmology and cancer. Like other pharmaceutical products that continue to soar during the recession, ALXN is up 64%, year-to-date.
Alkermes (NASDAQ:ALKS) is an integrated biotechnology company that attempts to treat prevalent, chronic diseases. Since the start of 2011, ALKS stock has gained 36%, compared to small gains by the broader markets.
Biogen Idec Inc. (NASDAQ:BIIB) is a biotechnology company that works with neurological disorders and other serious diseases. BIIB stock has jumped an impressive 75%, proving that pharmaceutical stocks can thrive during a down economy.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes pharmaceuticals including Naglazyme, Kuvan and Aldurazyme. BMRN has taken the ! lead of other Big Pharma stocks by gaining 18% year-to-date.
Cepheid (NASDAQ:CPHD) is a molecular diagnostics company that develops products for the clinical market. A 57% gain, year-to-date, for CPHD stock has left stockholders pleased with their purchase.
Curis Inc. (NASDAQ:CRIS) is a drug discovery company that develops target cancer therapies. CRIS stock is one of the big winners on this list, gaining 78% in just 10 months.
Nymox Pharmaceutical Corp. (NASDAQ:NYMX) is a biopharmaceutical company that markets an aid for the diagnosis of Alzheimer��s disease. NYMX stock has gained 27%, compared to much smaller gains by the broader markets.
Opko Health Inc. (AMEX:OPK) is a diagnostics and pharmaceutical company that focuses on molecular diagnostics tests, pharmaceuticals and vaccines. An impressive year-to-date return of 23% for OPK stock ensures a spot on this list.
Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is a commercial stage biopharmaceutical company working primarily with hematology, oncology and urology. SPPI stock is up 31% year-to-date, compared to a gain of just 2% for the Dow Jones.
Get more analysis of these picks and other publicly-traded stocks with Louis Navellier��s Portfolio Grader tool, a 100% free stock-rating tool that measures both quantitative buying pressure and eight fundamental factors.
Tags: ,AAPL ,ABT ,BK ,MS ,RIMM ,YHOO ,AAPL, YHOO, ABT, BK, MS, RIMM
No comments:
Post a Comment